Kexing Biopharm Co.,Ltd.’s Post

🏆 €1.36M awarded to AtG Therapeutics by Eurostars! Their project, 'Novel Intracellular Approach to Combat Renal Cancer', expedites the development of a first-in-class intracellular Tumour Adaptation-1 (TA-1) inhibitor for treatment of drug-resistant advanced renal cell carcinoma (RCC). With their TA-1 inhibitor, AtG Therapeutics address the high unmet need for effective drugs to overcome tumour resistance in late-stage RCC patients. “Our objective is to enhance the survival rates and quality of life of patients with advanced renal cancer.” Gabriela Jiménez Valerio, PhD., Co-Founder & COO, commented. We are proud of this result and pleased to share Gabriela's positive feedback of the collaboration: “Our experience with Catalyze was outstanding, and their support was instrumental in the success of our Eurostars application." 🔗 Read more here: https://lnkd.in/gvzTrhrS #AtGTherapeutics #Eurostars #renalcellcarcinoma #Catalyze

Did you know? #Therapeutics for #oncology often work for some time until inevitably resistance to the drug develops. The #cancer then comes back often in a much more aggressive manner. Scientists at Kairos Pharma have discovered a central mechanism responsible for the development of cancer drug resistance. As patients are treated with Xtandi, Zytiga, or Erleada or other anti-androgen drugs for prostate cancer or with Tagrisso, Tarceva, or Iressa for lung cancer, the cancer starts making a protein called CD105 on the cancer cell surface which makes the cancer resistant to those drugs. Our drug ENV105 is an antibody that reverses the effect of CD105, rendering the cancer responsive to those drugs again. NYSE: KAPA #KairosPharma #CancerTreatment #HealthcareInnovation #BioTech #PharmaTech #BioTechStock #PharmaStock #NYSE

Highlight Session of Day 1 at #SITC2024 Biotech Breakthroughs - Solid Tumor IO at the Tipping Point: This was an enlightening overview of some ground breaking Cell Therapies approved in the past year for solid tumors: #Amtagvi, from #Iovance Biotherapeutics, for aggressive Melanoma, February 2024 #Imdelltra, from #AMGEN, for Non-Small Cell Lung Cancer, May 2024 #Tecelra, from #Adaptimmune, for Advanced Synovial Sarcoma, August 2024 This was followed by exciting data from #Sapience Therapeutics, supporting the efficacy of #ST101 in Glioblastoma A lively panel discussion focused on: ·      The difficulty in monitoring recently approved T-cell receptor therapy in real world cancer patients in very busy cancer clinics without the same support/and resource allocation available during clinical trials ·      Ensuring T-cell receptor therapy are administering safely within a real world setting and dealing with new insurance approval processes ·      Upscaling the manufacturing of modified T-cells from a phase 1 academic center trial to a global scale is oftentimes a rate-limiting factor for a sponsor to move forward #CellTherapy #SolidTumors #Voiant

Sharing an article on some innovative biotechs in Denver-Boulder CO from Labiotech.eu. San Diego-based BioMed Realty, made a record-breaking $625 million purchase of Flatiron Park, a massive complex in Boulder, Colorado. Some interesting companies to highlight: Cerebral Therapeutics, CEO Dan Abrams, M.D. has created intracerebroventricular (ICV) therapies for people with neurological conditions. They currently are in trials for #epilepsy. Enliven Therapeutics, CEO Sam Kintz, is a clinical stage biotech immersed in the field of precision medicine for cancer. They currently have products in trials to target CML - chronic myeloid leukemia and NSCLC. OnKure Therapeutics, CEO Nicholas A. Saccomano Ph.D., are producing a PI3K inhibitor. PI3K is the most commonly mutated oncogene in cancer, particularly in estrogen receptor (ER)-positive breast cancer. Read the article here: https://lnkd.in/gz3qaP9E #denver #boulder #colorado #pharma #biotech #cancer #clinicaltrials #labinnovation

✨ Exciting developments and latest breakthroughs in oncology seen at #ESMO2024 This year’s ESMO Congress was the largest yet, with 33,336 attendees, 4,580 abstracts, and around 600 expert speakers in Barcelona. Companies like NiKang and JNJ showcased groundbreaking advancements in oncology, from a HIF-2α inhibitor for renal carcinoma to innovative bladder cancer treatments, marking significant progress in cancer therapy. These advances are shifting the focus from one-size-fits-all treatments to personalized therapies targeting specific mutations. Immunotherapies and CAR-T therapies are also offering new hope for patients. Comment below 👇 if you want more details of these readouts. Feel free to reach out at 📥 info@atacana.com if you'd like to learn more about the exciting developments in oncology or explore Atacana’s innovative solutions. #ESMO2024 #Oncology #Pharma #ClinicalResearch #Biotech #Investors #HealthcareInnovation #CancerResearch #NiKang #JohnsonandJohnson #Incyte #Amgen

Antrastuin® #Trastuzumab Injection) Included in Hefei's First Batch of New Material List Antrastuin® (Trastuzumab Injection) is an independently developed targeted anti-cancer drug by #AnkeBio, primarily used for the treatment of Her2-positive #breast cancer, metastatic #gastric cancer, and other malignant tumors. As the first antibody drug and the first biosimilar drug launched in Anhui Province, it does not require the use of preservatives and offers convenience through immediate preparation and use, bringing higher safety to clinical applications and providing more treatment options for domestic breast cancer patients, which holds significant clinical and societal value.

🎉 IDEAYA Biosciences and Biocytogen Advance Cancer Therapy with IDE034 Bispecific ADC! IDEAYA Biosciences is licensing Biocytogen’s B7H3/PTK7 bispecific antibody-drug conjugate (ADC), IDE034, as part of a $406.5M deal. This first-in-class ADC shows promising monotherapy results for cancers like lung and colorectal and offers a potential for combination with IDEAYA's existing drugs. IDE034, developed on Biocytogen's RenLite platform, aims for clinical trials by 2025, targeting dual antigens co-expressed in solid tumors. #OncologyInnovation #CancerTherapy #BiotechPartnership #ADC #DrugDevelopment #LifeSciences

Bayer announced that its Phase 3 clinical ARANOTE trial met its primary endpoint. Its oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) combined with androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). NUBEQA® (darolutamide) is an oral androgen receptor inhibitor with a distinct chemical structure that binds to androgen receptors with high affinity and exhibits strong antagonistic activity, thereby inhibiting receptor function and the growth of prostate cancer cells. Chemenu has been working to develop more compounds for drug discovery. Here come the building blocks we can provide: https://lnkd.in/gjqHGjDw # Darolutamide # NUBEQA # AR # ADT # mHSPC # Chemenu # building blocks

Interferon alpha-2 enters the precision medicine era: Nammi Therapeutics, Inc. just dosed their first patient with QXL138AM, and the approach is rather clever. The science here is fascinating - instead of accepting the systemic toxicity that usually limits interferon therapy, they've created a masked immunocytokine that only activates at the tumor site. The antibody portion targets CD138+ cancer cells, the interferon stays masked until it reaches the tumor, and local proteases unmask it right where it needs to work. What's particularly interesting is how they're approaching development: starting with CD138+ cancers ✓ potential for both solid tumors and multiple myeloma ✓ already secured Orphan Drug Designation in pancreatic cancer ✓ and planning to let early clinical data guide their expansion strategy. Could this finally be the way to harness interferon's anti-cancer potential without the systemic side effects? #CancerTherapy #PrecisionMedicine #Immunocytokines #ClinicalTrials

Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/eaxfqX showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/7Y36P0 🤝 #ChemoMetec #NucleoCounter #IovanceBiotherapeutics #Cellcounting